Login / Signup

Aldosterone as a possible contributor to eye diseases.

Tomomi HigashideKazuyuki HirookaMitsuhiro KometaniKazuhisa Sugiyama
Published in: Endocrinology (2022)
Aldosterone, an effector molecule of the renin-angiotensin-aldosterone system (RAAS), has been receiving more attention in the field of ophthalmology because of its possible role in the pathogenesis of various eye diseases or abnormalities; potentially, it may even become a target for their treatment. Primary aldosteronism, a typical model of a systemic aldosterone excess, may cause vision loss due to various ocular diseases, such as retinal vein occlusion, central serous chorioretinopathy, and possibly, glaucoma. RAAS components are present in various parts and types of cells present in the eye. Investigations of local RAAS in various animal models of diabetic macular edema, retinal vein occlusion, retinopathy of prematurity, central serous chorioretinopathy, and glaucoma have found evidence that aldosterone or mineralocorticoid receptors may exacerbate the pathology of these disorders. Further studies are needed to elucidate whether the modulation of aldosterone or mineralocorticoid receptors is an effective treatment for preventing vision loss in patients with eye diseases.
Keyphrases
  • angiotensin ii
  • optic nerve
  • angiotensin converting enzyme
  • high grade
  • optical coherence tomography
  • cell cycle arrest
  • signaling pathway
  • dendritic cells
  • replacement therapy
  • pi k akt